Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers

被引：7

作者：

Coulter, Jonathan B. ^{[1
]}

Easwaran, Hariharan ^{[2
]}

机构：

[1] Johns Hopkins Univ, Brady Urol Inst, Sch Med, Baltimore, MD USA

[2] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Canc Genet & Epigenet, Oncol,Sch Med, Baltimore, MD 21231 USA

来源：

PLOS BIOLOGY | 2023年 / 21卷 / 04期

关键词：

POLYCOMB;

D O I：

10.1371/journal.pbio.3002081

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard therapies.

引用

页数：4

共 50 条

[21] Small molecule inhibitors of EZH2: the emerging translational landscape [J].

Keilhack, Heike ;

Smith, Jesse J. .

EPIGENOMICS, 2015, 7 (03) :337-341

[22] Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers [J].

Cohen, Adam L. ;

Piccolo, Stephen R. ;

Cheng, Luis ;

Soldi, Rafaella ;

Han, Bing ;

Johnson, W. Evan ;

Bild, Andrea H. .

BMC MEDICAL GENOMICS, 2013, 6

[23] Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer [J].

Kong, Yifan ;

Zhang, Yanquan ;

Mao, Fengyi ;

Zhang, Zhuangzhuang ;

Li, Zhiguo ;

Wang, Ruixin ;

Liu, Jinghui ;

Liu, Xiaoqi .

MOLECULAR CANCER THERAPEUTICS, 2020, 19 (12) :2490-2501

[24] Identification of potential inhibitors for EZH2/PRC2 in cancer cells [J].

Murashima, Akihiro ;

Shinjo, Keiko ;

Dohi, Natsuki ;

Katsushima, Keisuke ;

Ito, Akihiro ;

Onuki, Tetsuo ;

Yoshida, Minoru ;

Kondo, Yutaka .

CANCER SCIENCE, 2018, 109 :621-621

[25] EZH2 as a novel therapeutic target for atrial fibrosis and atrial fibrillation [J].

Song, Shuai ;

Zhang, Rui ;

Mo, Binfeng ;

Chen, Long ;

Liu, Liang ;

Yu, Yi ;

Cao, Wei ;

Fang, Guojian ;

Wan, Yi ;

Gu, Yue ;

Wang, Yuepeng ;

Li, Yigang ;

Yu, Ying ;

Wang, Qunshan .

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2019, 135 :119-133

[26] Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells [J].

Jin, Mengyuan ;

Duan, Jiachen ;

Liu, Wei ;

Ji, Jing ;

Liu, Bin ;

Zhang, Mingzhi .

CANCER CELL INTERNATIONAL, 2021, 21 (01)

[27] Dual-target EZH2 inhibitor: latest advances in medicinal chemistry [J].

Wei, Lai ;

Mei, Dan ;

Hu, Sijia ;

Du, Shufang .

FUTURE MEDICINAL CHEMISTRY, 2024, 16 (15) :1561-1582

[28] Prognostic significance of EZH2 expression in patients with digestive cancers: a meta-analysis [J].

Wang, Wei ;

Wang, Feng ;

Zong, Guangquan ;

Liu, Renmin ;

Zhang, Yufei ;

Luan, Yang ;

Xu, Lin ;

Xuan, Ji .

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (09) :16043-16049

[29] USP7 deubiquitinates and stabilizes EZH2 in prostate cancer cells [J].

Lee, Jae Eun ;

Park, Chan Mi ;

Kim, Jung Hwa .

GENETICS AND MOLECULAR BIOLOGY, 2020, 43 (02) :1-12

[30] A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors [J].

Liang, Rui ;

Tomita, Daisuke ;

Sasaki, Yusuke ;

Ginn, John ;

Michino, Mayako ;

Huggins, David J. ;

Baxt, Leigh ;

Kargman, Stacia ;

Shahid, Maaz ;

Aso, Kazuyoshi ;

Duggan, Mark ;

Stamford, Andrew W. ;

DeStanchina, Elisa ;

Liverton, Nigel ;

Meinke, Peter T. ;

Foley, Michael A. ;

Phillips, Richard E. .

ACS MEDICINAL CHEMISTRY LETTERS, 2022, 13 (03) :377-387

← 1 2 3 4 5 →